Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 255 in NAFLD and Hyperoxaluria
NCT06138327Phase 1Withdrawn
- Sponsor
- BioMarin Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperoxaluria comparing BMN 255 with Placebo (2 arms). Primary endpoints: Incidence of adverse events and 24-hour urine oxalate levels. Planned start Sep 2023; status: withdrawn.
02
Drugs
BMN 255
03
Conditions
hyperoxaluria
Beyond the preview
Go deeper on NCT06138327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138327.